The pharma stock collapsed on the threat of generic competition for a drug that launched in December 2019, but the move may have been a bit of an overreaction.
News & Analysis: Amarin
The arrival of a generic version of Vascepa will be bad news for the company.
U.S. patents protecting the only revenue source for this biotech company were recently invalidated, and the dust won't settle anytime soon.
Not all IPO returns are equal.
AMRN earnings call for the period ending March 31, 2020.
Amarin and Atara Biotherapeutics could both be diamonds in the rough.
Could both of these volatile stocks be winners in the long run?
Did investors overreact to its invalidated patents?
The definitive answer is...
AMRN earnings call for the period ending April 13, 2020.